EGFR and neutropenia: The combination of amivantamab plus chemotherapy aims to enhance tumor response.32 In studies investigating amivantamab plus chemotherapy, certain AEs were more commonly observed compared with amivantamab monotherapy, including neutropenia, thrombocytopenia, anemia, leukopenia, asthenia, nausea, constipation, and decreased appetite (Figure 4).28,40,44 These higher incidences are likely due to both the increased drug burden of combination therapy and the addition of chemotherapy-associated AEs to those associated with EGFR and MET inhibition.